Ampac Fine Chemicals has acquired a fine chemicals manufacturing facility in LaPorte, TX. The $475,000, plus costs, acquisition increases the company's capacity by 30%. The facility, which passed FDA in 2008, was completed in 2001 and significant new equipment was added in the last four years. Aslam Malik, President of Ampac said "this additional capability in Texas, which includes commercial scale hydrogenation, as well as azide, cyanide, and phosgene capabilities, fits well with our areas of established expertise in energetic chemistry and continuous processing."
Ampac
Monday, 12 April 2010
Ampac acquires Texas facility
Wednesday, 7 April 2010
Thursday, 1 April 2010
Ranbaxy to use Pfenex technology
Ranbaxy will develop an undisclosed biosimilar therapeutic using Pfenex's Pseudomonas-based recombinant protein expression technology. The two companies will develop production strains and the production process for the product.
Business Standard
Monday, 29 March 2010
Ampac confirms manufacturing deal with Codexis
Ampac Fine Chemicals will use Codexis' proprietary biocatalysis technology to develop lower cost, more efficient and lower environmental impact processes for pharmaceutical intermediates and APIs.
PR Newswire
Lonza cuts jobs in Visp
Lonza continues to announce measures to meet the cutbacks announced last year. The company plans to cut fixed costs in Basel and Visp by CHF40m over the next 18 months, which will include 193 jobs at Visp.
Lonza
Wednesday, 24 March 2010
Borgas rebrands fine chemicals
Speaking at the Socma dinner in New York, Lonza CEO, Stefan Borgas, said that the industry needed to consider itself the "fine molecules" sector as the products it makes are no longer just chemicals. He said the future of the industry lay in companies reinventing their current business models and taking a more collaborative approach to innovation.
Icis
Thursday, 18 March 2010
Wednesday, 17 March 2010
Successful audits for Jubilant facilities
Jubilant Organosys' Hollister-Stier's Spokane, WA, facility completed a successful audit by the Japanese Pharmaceutical and Medical Device Agency (PMDA) and its Draxis Pharma Montreal, Canada, facility completed a successful audit by the US FDA and Health Canada.
Hollister-Stier
UKTI and Chemspec Europe
UKTI and Chemspec Europe
UK Trade & Investment is co-ordinating a UK pavillion at Chemspec Europe in June. Grants are available to potential exhibiters. Contact Tricia Francis for more details.
Sunday, 14 March 2010
AutekBio to establish Chinese biologics facility
AutekBio, SUMA Ventures and Beijing E-Town Harvest International Capital Management Corporation will jointly invest $100m to develop a new biopharmaceutical contract manufacturing organisation in China. The joint venture will build an R&D and manufacturing center in southern Beijing with up to 20,000L capacity in multiple trains.
Business Wire
Partnership offers CMC services
Cambridge Major Laboratories has teamed up with Avantium Pharma, Xcelience and Beckloff Associates to offer an expedited CMC solutions program designed to accelerate drug development. The service is available to companies ranging from small biotechs to big pharma.
Fierce Pharma Manufacturing
Wacker refocusses pharma-facing activities; opens biologics plant
Wacker Chemie has restructured its biotech and fine-chemical segment. The Wacker Biosolutions division, formerly known as Wacker Fine Chemicals, will focus on services for the food, pharmaceuticals and agrochemicals sectors alongside its existing portfolio of fine chemicals and chemical intermediates. Additionally, Wacker has opened a new €18m GMP-certified biologics facility in Jena, Germany, to enable the company to accommodate its customers’ rapidly growing demand for biotechnologically manufactured pharmaceuticals.
Wacker
In-Pharma Technologist
Aurobindo company launches CRAMS subsidiary
Indian pharmaceutical company Aurobindo Pharma has launched a subsidiary to provide CRAMS services. AuroSource will partner with global large, mid-sized and emerging biotech and pharmaceutical companies.
In-Pharma Technologist
Thursday, 4 March 2010
Wednesday, 3 March 2010
Tuesday, 2 March 2010
Dishman's Shanghai facility delayed
Dishman Chemicals and Pharmaceuticals Shanghai, China, facility has been further delayed by a couple of months. VVS Murthy, chief financial officer, expects the facility to start functioning from the second half of 2010, maybe August-September 2010. Dishman has invested $10m in the project.
DNA India
Wednesday, 24 February 2010
Pharma sales decline at DSM
Full year 2009 sales for DSM declines 11% as a result of low demand from pharmaceutical companies, delay in approvals and the loss of some large contracts. In addition the company recognised a non-cash goodwill impairment charge of €154m from its acquisition of Catalytica.
DSM
Aesica plans expansion
Aesica is seeking to acquire manufacturing facilities in the US and Europe and to add high containment capabilities at one of its sites. The company believes that adding US facilities will help it attract contracts from US pharma customers.
In-pharma Technologist
Monday, 22 February 2010
Recipharm launches new biologics unit
Following its acquisition of Cobra Biomanufatcuring, Recipharm has combined the two biologics manufacturing businesses into an integrated business, RecipharmCobra Biologics.
Recipharm
Saturday, 20 February 2010
EMS Chemie interested in Lonza?
Lonza shares rose on market rumours that EMS Chemie is considering acquiring the company.
Reuters
Thursday, 18 February 2010
AMRI acquires Excelsyn
Excelsyn has been acquired by AMRI for $19m. The Holywell, Wales-based business, which was formerly part of Great Lakes, includes kilo lab, pilot plant and large scale manufacturing capabilities. AMRI Chairman and CEO Thomas D’Ambra said, "The acquisition of Excelsyn further builds out AMRI's global continuum and will increase our ability to penetrate a market space relatively untapped to date, including customers in large pharma based in Europe."
Ian Shott, President and Chief Executive of Excelsyn, acquired the Holywell business in 2004 for a £3m package including debt.
Albany Times Union
Wednesday, 17 February 2010
Codexis selects Dishman and Ampac Fine Chemicals
Dishman has been selected as the preferred contract manufacturer for Codexis. Dishman will use Codexis' biocatalysis technology to manufacture building blocks, intermediates and APIs for innovator pharmaceutical companies. Dishman will also offer the technology to its own customers. Codexis will also collaborate with Ampac Fine Chemicals to expand the application of its technology.
Codexis
Monday, 15 February 2010
Albemarle to provide manufacturing for PharmaCore customers
Albemarle will provide manufacturing services for PharmaCore customers with projects that require high volume capacity. The alliance will allow seamless technology transfer when customers require higher volumes of APIs and active ingredients.
Albemarle
Saturday, 13 February 2010
Aurelius acquires Isochem
German private equity house Aurelius has acquired Isochem from SNPE for €8m. SNPE will take on €50m in debt from Isochem. The deal is subject to approval by the SNPE board. Unions at Isochem are opposed to the deal and are expected to call for a strike. Aurelius was one of five potential acquirers and was given exclusive negotiating rights in December.
Les Echos
Cambrex sales decline in Q4
Cambrex sales decreased by 9.9% in Q4 2009 and full year sales were down 5.3% on 2008. The company said the decrease is primarily due to lower volumes of an API that utilises its polymeric drug delivery technology, lower sales of two APIs manufactured under long-term supply agreements and lower custom development revenues.
Cambrex
Year ends with an upturn for SAFC
Sigma-Aldrich's fine chemicals business, SAFC, had its best quarter of 2009 in Q4, meeting the company's expectations of improved sales as the year ended. CFO, Rakesh Sachdev, put this down to "continued demand for adjuvant products for the H1N1 vaccine production and industrial media for pharmaceutical customers, as well as customer efforts to push early stage clinical trials".
Seeking Alpha
Wednesday, 10 February 2010
EFCG welcomes excipient amendments
The addition of excipient GMP requirements to the draft amendments of the EU falsified medicines directive has been welcomed by the European Fine Chemicals Group.The European Commission's Committee on the Environment, Public Health and Food Safety (ENVI) has proposed GMP requirements for excipients in its draft opinion.
In-Pharma Technologist
Wednesday, 3 February 2010
Dishman restructures Carbogen Amcis
Dishman is restructuring its Carbogen Amcis subsidiary. Staff levels have been cut by 20% and a new CEO - currently working at another company in the sector - will join in March. Q3 sales at Carbogen Amcis fell 27% this year and the company expects to save CHF8m through the restructuring.
Business Standard
Tuesday, 2 February 2010
SynCo signs US deal
SynCo Bio Partners will provide process validation and GMP commercial manufacturing services to support the commercial launch of two separate biopharmaceutical products, from an unnamed company, for the US market. The recombinant proteins will be produced in E. coli.
SynCo BioPartners
UKTI and Chemspec USA
UK Trade and Investment is considering running a UK pavilion at the inaugural Chemspec USA show in Philadelphia in May 2011. For further information contact Tricia Francis.
Watson acquires Eden
Eden Biodesign has been acquired by Watson Pharmaceuticals for $15m. Watson had previously acquired 36% of the business through a previous acquisition last year. Following the acquisition Eden will continue to offer contract manufacturing services.
Business Week
Tough year for Lonza in 2009; cautiously optimistic for 2010
Lonza's full year results showed a 8.4% fall in sales in 2009 compared to 2008. The company said that clinical results had driven order reductions for its biopharmaceutical manufacturing business. CEO, Stefan Borgas remains optimistic for the future and said the company's previously announced re-engineering would help generate cash flow in 2010.
In-Pharma Technologist
Wednesday, 27 January 2010
Albemarle fine chemicals sales decline
Sales for Albemarle's Fine Chemicals segment were down 10% - to $146m - in Q4 2009 compared to 2008. The company has seen fine chemicals sales and profitability steadily increase over the past three quarters. Mark Rohr, Albemarle's Chairman, President and CEO, said the company was looking at a number of bolt-on acquisitions to continue growth, primarily in its fine chemicals business.
Seeking Alpha
Monday, 25 January 2010
Merck builds pharma salts plant
Merck KGaA has started construction work on a pharmaceutical inorganic salts manufacturing plant in Darmstadt, Germany. The €30m investment will add 50% to the company's current capacity and is expected to be online in mid-2011.
Merck
Thursday, 21 January 2010
Wednesday, 20 January 2010
German grant for downstream processing research
A German research consortium including Rentschler Biotechnology and Boehinger Ingelheim has received €3.2m to develop a pioneering scalable purification method that could cut the cost of downstream protein processing by up to 90%.
Euro Biotech News
Monday, 18 January 2010
Dishman to build four API plants
Dishman plans to build four new API plants, two of which are due to be operational by March 2011 and two by 2012. Dishman will invest $27.4m on the expansion, the majority of which will be from the previously announced fundraising. J R Vyas, Dishman's managing director, said the new plants will increase capacity 400m3.
Economic Times
Lonza closes API plant
Lonza will close its API manufacturing facility at Riverside, PA. Production will be moved to Lonza's other facilities in Europe and China. The closure will affect 175 employees and cost €94.5m.
In-Pharma Technologist
Wednesday, 6 January 2010
Dishman seeks 20% growth in CRAMS
Dishman is expecting growth of about 20% for its CRAMS segment in the next year according to cfo V V S Murthy. He put this down to easing of inventory rationalisation by big pharma and increasing outsourcing to India.
DNA India
26 drugs approved in 2009
The FDA approved 26 new drugs in 2009 - just one more than in 2008. Of these seven were biologics and 19 small molecules according to analysts at Washington Analysis.
Wall Street Journal
Subscribe to:
Posts (Atom)
